expressing primary afferents by [d-ala2,n-me-phe4,gly-ol5...
TRANSCRIPT
JPET #141226
1
Sustained Inhibition of Neurotransmitter Release from non-TRPV1-
Expressing Primary Afferents by [D-Ala2,N-Me-Phe4,Gly-ol5]-Enkephalin in
the Spinal Cord
Hong-Yi Zhou, Shao-Rui Chen, Hong Chen, and Hui-Lin Pan
Department of Anesthesiology and Pain Medicine (HYZ, SRC, HC, HLP)
The University of Texas M. D. Anderson Cancer Center
Houston, TX 77030
and
Program in Neuroscience (HLP)
The University of Texas Graduate School of Biomedical Sciences
Houston, TX 77225
JPET Fast Forward. Published on July 31, 2008 as DOI:10.1124/jpet.108.141226
Copyright 2008 by the American Society for Pharmacology and Experimental Therapeutics.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
2
Running title: Primary afferent phenotypes and µ-opioid receptors List of Abbreviations:
Griffonia simplicifolia isolectin B4 (IB4); [D-Ala2,N-Me-Phe4,Gly-ol5]-enkephalin (DAMGO);
transient receptor potential vanilloid type 1 (TRPV1); excitatory postsynaptic currents (EPSCs);
miniature excitatory postsynaptic currents (mEPSCs); G protein-coupled inwardly rectifying K+
channels (GIRK)
Number of text pages: 33;
Number of tables: 0;
Number of figures: 8;
Abstract, 244;
Introduction, 454;
Discussion, 1413;
Number of references: 32
Address for correspondence: Hui-Lin Pan, M.D., Ph.D. Department of Anesthesiology and Pain Medicine, Unit 110 The University of Texas M. D. Anderson Cancer Center 1515 Holcombe Blvd. Houston, TX 77030 Tel: (713) 563-5838 Fax: (713) 794-4590 email: [email protected]
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
3
Abstract
Removing transient receptor potential vanilloid type 1 (TRPV1)-expressing primary
afferent neurons reduces presynaptic µ-opioid receptors but potentiates opioid analgesia.
However, the sites and underlying cellular mechanisms for this paradoxical effect remain
uncertain. In this study, we determined the presynaptic and postsynaptic effects of the µ-opioid
receptor agonist (D-Ala2,N-Me-Phe4,Gly-ol5)-enkephalin (DAMGO) using whole-cell patch-
clamp recordings of lamina II neurons in rat spinal cord slices. Treatment with the ultrapotent
TRPV1 agonist resiniferotoxin (RTX) eliminated TRPV1-expressing DRG neurons and their
central terminals in the spinal dorsal horn and significantly reduced the basal amplitude of
glutamatergic excitatory postsynaptic currents (EPSCs) evoked from primary afferents.
Although RTX treatment did not significantly alter the concentration-response effect of
DAMGO on evoked monosynaptic and polysynaptic EPSCs, it causes a profound long-lasting
inhibitory effect DAMGO on evoked EPSCs. Subsequent naloxone treatment did not reverse
the prolonged inhibitory effect of DAMGO on evoked EPSCs. Furthermore, brief application of
DAMGO produced a sustained inhibition of miniature EPSCs in RTX-treated rats. However,
the concentration-response and the duration of DAMGO’s effect on G protein-coupled inwardly
rectifying K+ currents in lamina II neurons were not significantly different between vehicle- and
RTX-treated groups. These data suggest that stimulation of µ-opioid receptors on non-TRPV1
afferent terminals causes extended inhibition of neurotransmitter release to spinal dorsal horn
neurons. The differential effect of µ-opioid receptor agonists on different phenotypes of primary
afferents provides a cellular basis to explain why the analgesic action of opioids on mechano-
nociception is prolonged when TRPV1-expressing primary afferents are removed.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
4
Introduction
The primary afferent neurons and the spinal cord are critically involved in pain
transmission and modulation and are the important sites for the analgesic action of µ-opioid
receptor agonists (Yaksh and Noueihed, 1985; Magnuson and Dickenson, 1991; Kohno et al.,
1999; Chen and Pan, 2006a). The µ-opioid receptors are located presynaptically on primary
afferent terminals (Fields et al., 1980; Kohno et al., 1999; Abbadie et al., 2002) and on
postsynaptic dorsal horn neurons (Light and Willcockson, 1999; Marker et al., 2006).
Presynaptically, the µ-opioid receptor agonists reduce excitatory neurotransmitter release
through presynaptic inhibition of voltage-gated Ca2+ channels (Rusin and Moises, 1995; Wu et
al., 2004) and direct inhibition of synaptic vesicle releases (Blackmer et al., 2005; Gerachshenko
et al., 2005). However, the contributions of µ-opioid receptors distributed on different
phenotypes of primary afferent terminals to the opioid analgesia are not clear.
The capsaicin receptor transient receptor potential vanilloid type 1 (TRPV1) plays an
essential role in detecting thermal nociception (Caterina et al., 2000). Furthermore, removing
TRPV1-expressing dorsal root ganglion (DRG) neurons by resiniferatoxin (RTX), an ultrapotent
TRPV1 agonist, impairs thermal nociception in adult rats (Chen and Pan, 2006b). It has been
shown that TRPV1 antagonists reduce mechanical nociception in acute and chronic pain models
(Walker et al., 2003; Cui et al., 2006). Interestingly, although RTX induces a substantial
reduction in presynaptic µ-opioid receptors, it potentiates and prolongs the analgesic effect
produced by systemic or intrathecal injection of µ-opioid receptor agonists, including morphine
and DAMGO (Chen and Pan, 2006b). Removal of TRPV1-expressing sensory neurons by RTX
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
5
also attenuates the development of morphine analgesic tolerance (Chen et al., 2007). However,
the cellular and molecular mechanisms underlying this paradoxical opioid action in RTX-treated
rats are unclear. The phenotypes and functions of DRG neurons, even among the small-diameter
neurons, are highly heterogeneous. It has been shown that the µ-opioid agonists have a greater
effect on voltage-gated Ca2+ channels in IB4-negative small-sized DRG neurons than in IB4-
positive (mostly TRPV1-expressing) ones (Wu et al., 2004). Furthermore, the µ-opioid receptor
agonists such as morphine reduce the mechanical nociception far longer than thermal
nociception (Chen and Pan, 2006a). The potential difference in the functional activity of µ-
opioid receptors on TRPV1- and non-TRPV1-expressing afferent terminals has not been
determined previously.
The aim of the present study, therefore, was to determine whether removing TRPV1-
expressing sensory neurons alters the presynaptic and postsynaptic effects of the µ-opioid
receptor agonist in the spinal cord. Our findings provide new evidence that loss of TRPV1-
expressing sensory neurons causes the µ-opioid receptor agonist to have a profound, long-lasting
presynaptic, but not postsynaptic, effect in the spinal dorsal horn. This information is important
for our understanding of the functions of the µ-opioid receptors present in different phenotypes
of primary afferent neurons.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
6
Methods
Animals and RTX treatment
Male Sprague-Dawley rats (130-150 g; Harlan, Indianapolis, IN) were used in this study.
Rats received a single intraperitoneal injection of RTX (200 µg/kg, LC Laboratories, Woburn,
MA) while under 2-3% isoflurane anesthesia, and the anesthesia was maintained for 3 h after
RTX injection (Chen and Pan, 2006b). RTX was dissolved in a mixture of 10% Tween-80 and
10% ethanol in normal saline. Rats in the control group received intraperitoneal injection of
vehicle alone. The final electrophysiological experiments were conducted 4 weeks after RTX
and vehicle injections. All the surgical preparation and experimental protocols were approved
by the Animal Care and Use Committee of the University of Texas M. D. Anderson Cancer
Center and conformed to the National Institutes of Health guidelines for the ethical use of
animals.
Behavioral assessment of thermal nociception
To quantitatively assess the thermal nociceptive threshold, rats were placed on the glass
surface of a thermal testing apparatus (IITC Inc., Woodland Hills, CA). The rats were allowed to
acclimate for 30 min before testing. The temperature of the glass surface was maintained
constant at 30EC. A mobile radiant heat source located under the glass was focused onto the
hindpaw. The paw withdrawal latency was recorded using a timer. A cutoff of 30 s was used to
prevent potential tissue damage (Chen and Pan, 2006a).
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
7
Double fluorescence labeling of TRPV1 and IB4 in DRGs and spinal dorsal horn
To ensure the effect of RTX treatment on TRPV1-expressing DRG neurons and
terminals, double labeling of TRPV1 and Griffonia simplicifolia isolectin B4 (IB4, a cellular
marker for unmyelinated afferent fibers) in DRG neurons and the spinal dorsal horn was
performed on three vehicle- and three RTX-treated rats 4 weeks after treatment (Chen and Pan,
2006b). Under deep anesthesia (pentobarbital sodium, 60 mg/kg, ip), each rat was intracardially
perfused with 4% paraformaldehyde and 10% sucrose. The lumbar spinal cord and L4 and L5
DRGs were removed and postfixed in the same fixative solution and cryoprotected in 30%
sucrose in PBS for 48 h at 4EC. The tissues were cut to 30 µm in thickness and collected free-
floating in 0.1 M PBS. For TRPV1 labeling, the sections were first blocked in 4% normal goat
serum in PBS for 1 h. The sections were then incubated with the primary antibody (rabbit anti-
TRPV1 N-terminus, dilution 1:1000, Neuromics, Minneapolis, MN) diluted in PBS containing
2% normal goat serum and 0.3% TX-100 for 2 h at room temperature and overnight at 4EC.
Subsequently, sections were incubated with the secondary antibody (Alexa Fluor-488 conjugated
to goat anti-rabbit IgG, dilution: 5 µg/ml, Molecular Probes, Eugene, OR). The sections then
were rinsed in PBS and incubated with Alexa Fluor-594 conjugated to IB4 (dilution: 2 µg/ml,
Molecular Probes) for 2 h at room temperature. Finally, the sections were mounted on slides,
dried, and coverslipped. The sections were examined on a laser scanning confocal microscope
(Zeiss, Germany), and areas of interest were photodocumented. Omission of the primary
antibody results in negative labeling in all the sections examined.
Spinal cord slice preparation
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
8
With the rats under 2-3% isoflurane anesthesia, we removed the lumbar segment of the
spinal cord by means of laminectomy. This spinal cord segment was immediately placed in an
ice-cold sucrose artificial cerebrospinal fluid (aCSF) presaturated with 95% O2 and 5% CO2.
The sucrose aCSF contained (in mM) 234 sucrose, 3.6 KCl, 1.2 MgCl2, 2.5 CaCl2, 1.2
NaH2PO4, 12.0 glucose, and 25.0 NaHCO3. The tissue was then placed in a shallow groove
formed in a gelatin block and glued on the stage of a vibratome (Technical Product
International, St. Louis, MO). Transverse spinal cord slices (400 µm) were cut in the ice-cold
sucrose aCSF and then preincubated in Krebs solution oxygenated with 95% O2 and 5% CO2 at
34EC for at least 1 hour before being transferred to the recording chamber. The Krebs solution
contained (in mM) 117.0 NaCl, 3.6 KCl, 1.2 MgCl2, 2.5 CaCl2, 1.2 NaH2PO4, 11.0 glucose, and
25.0 NaHCO3.
Electrophysiological recordings
Postsynaptic currents were recorded using the whole-cell voltage-clamp method, as we
described previously (Zhang et al., 2007; Zhou et al., 2007). The slice was placed in a glass-
bottomed chamber (Warner Instrument, Hamden, CT) and fixed with parallel nylon threads
supported by an U-shaped stainless steel weight. The slice was continuously perfused with
Krebs solution at 5.0 ml/min at 34EC maintained by an inline solution heater and a temperature
controller (TC-324; Warner Instrument). The lamina II was identified by light microscopy as a
distinct translucent band across the superficial dorsal horn. The neurons in the lamina II of the
spinal cord slice were identified by fixed-stage microscopy (BX50WI; Olympus, Tokyo, Japan)
with differential interference contrast/infrared illumination. The spinal lamina II neurons were
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
9
studied because they receive predominantly nociceptive input from both TRPV1- and non-
TRPV1-expressing C-fiber afferent terminals (Woodbury et al., 2000; Pan et al., 2003).
Monosynaptic and polysynaptic excitatory postsynaptic currents (EPSCs) were evoked
by electrical stimulation (0.6 mA, 0.2 ms) of the dorsal root or dorsal root entry zone (Zhang et
al., 2007). The electrode for the whole-cell recordings was pulled from borosilicate glass
capillaries with a puller (P-97; Sutter Instrument Company, Novato, CA). The impedance of the
pipette was 3-5 MΩ when filled with internal solution containing (in mM) 110 Cs2SO4, 5 TEA,
2.0 MgCl2, 0.5 CaCl2, 5.0 HEPES, 5.0 EGTA, 5.0 ATP-Mg, 0.5 Na-GTP, 1 guanosine 5'-O-(2-
thiodiphosphate) (GDP-β-S), and 10 lidocaine N-ethyl bromide (QX314) that had been adjusted
to pH 7.2 to 7.4 with 1 M CsOH (290-300 mΩsm). To examine the presynaptic effect of the µ-
opioid receptor agonist (D-Ala2,N-Me-Phe4,Gly-ol5)-enkephalin (DAMGO), GDP-β-S and K+
channel blockers (Cs+ and TEA) were added to the internal solution to inhibit the postsynaptic
effect of DAMGO. QX314 was added into the internal solution to suppress the action potential
generation from the recorded cell. The evoked EPSCs were considered to be monosynaptic if: 1)
the latency was constant with repeated electrical stimulation at 0.1 Hz, and 2) there was no
conduction failure or increased latency when stimulation frequency was increased to 20 Hz
(Zhang et al., 2007). In contrast, evoked EPSCs were considered polysynaptic if the latency was
variable and conduction failure occurred at the higher stimulation frequency (20 Hz). To record
the miniature EPSCs (mEPSCs), 1 µM tetrodotoxin (TTX) was added to the perfusion solution.
To study the postsynaptic effect of the opioid agonist, G protein-coupled inwardly
rectifying potassium (GIRK) currents induced by DAMGO were recorded in lamina II neurons
(Marker et al., 2006). The impedance of the pipette was 5-10 MΩ when filled with internal
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
10
solution containing (in mM) 135.0 potassium gluconate, 5.0 TEA, 2.0 MgCl2, 0.5 CaCl2, 5.0
HEPES, 5.0 EGTA, 5.0 ATP-Mg, 0.5 Na-GTP; the solution was adjusted to pH 7.2 to 7.4 with 1
M KOH (290-300 mΩsm). GDP-β-S and QX-314 were not included in the intracellular solution
for the recording of GIRK currents.
Recordings of evoked EPSCs, mEPSCs, and GIRK currents began about 6 min after
whole-cell access was established and the current reached a steady state. The input resistance
was monitored, and the recording was abandoned if it changed more than 15%. All signals were
recorded using an amplifier (MultiClamp700B; Axon Instruments Inc., Union City, CA) at a
holding potential of -60 mV, filtered at 1-2 kHz, digitized at 10 kHz, and stored into a computer
with pCLAMP 9.2 (Axon Instruments Inc.). DAMGO, naloxone, and GDP-β-S were obtained
from Sigma-Aldrich (St. Louis, MO). TTX and QX314 was obtained from Alomone Labs
(Jerusalem, Israel). Drugs were dissolved in Krebs solution and perfused into the tissue chamber
using syringe pumps.
Data analysis and statistics
Data are presented as means ± S.E.M. The amplitudes of evoked EPSCs and GIRK
currents were analyzed off-line with Clampfit 9.2 (Axon Instruments Inc.). The dose-response
effects of DAMGO on evoked EPSCs, mEPSCs, and GIRK currents were determined by either
two-way or repeated measures analysis of variance. The ED50 value of the DAMGO effect was
determined by nonlinear regression analysis of the concentration–response data using Prism
(GraphPad Software, San Diego, CA). Differences in the duration of DAMGO’s effect on GIRK
currents were analyzed using Student's t-test. Differences with P < 0.05 were considered to be
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
11
statistically significant.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
12
Results
Effect of RTX on the thermal nociceptive threshold
Systemic injection of RTX caused a large increase in the paw-withdrawal threshold in
response to the noxious heat stimulus. In all of the RTX-treated rats, there was a large increase
in the paw withdrawal threshold in response to the heat stimulus as tested one week after RTX
injection (24.32 ± 2.34 vs. 9.66 ± 1.42 s pre-treatment, n = 18, P < 0.05). The impaired thermal
nociception persisted for at least 4 weeks after RTX injection. In contrast, systemic injection of
the vehicle did not significantly alter the paw withdrawal threshold in response to the noxious
heat (9.48 ± 1.41 vs. 9.51 ± 1.38 s pre-treatment, n = 16).
Effect of RTX on TRPV1 and IB4 labeling in the DRG and spinal cord
TRPV1 immunoreactivity and IB4-labeling were predominantly present in small- and
medium-sized DRG neurons in vehicle-treated rats. IB4-labeling was present in the majority of
TRPV1-immunoreactive DRG neurons (Fig. 1A). In RTX-treated rats, the TRPV1-
immunoreactive DRG neurons were largely eliminated (Fig. 1A). IB4-positive neurons were also
substantially reduced in the DRG sections from RTX-treated rats. The loss of TRPV1- and IB4-
positive DRG neurons by RTX treatment has been quantified in our previous study (Chen and
Pan, 2006b).
In vehicle-treated rats, TRPV1-immunoreactive- and IB4-positive terminals were present
in the superficial dorsal horn of the spinal cord (Fig. 1B). Dense TRPV1 immunoreactivity was
seen both at the dorsal root entry zone and in laminas I and II. TRPV1 immunoreactivity
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
13
appeared largely co-localized on the same terminals labeled with IB4 in the laminas I and II of
rats treated with the vehicle. By contrast, the TRPV1-immunoreactive terminals were
completely abolished in the spinal dorsal horn of RTX-treated rats (Fig. 1B). Also, IB4-positive
terminals were markedly decreased in the superficial spinal dorsal horn of RTX-treated rats.
Notably, in the vehicle-treated rats, there was a subpopulation of TRPV1-immunoreactive dorsal
horn neurons. Similar to the results in our previous study (Chen and Pan, 2006b), these TRPV1-
immunoreactive neurons in the spinal dorsal horn were not affected in RTX-treated rats.
Effect of DAMGO on evoked glutamatergic EPSCs in the spinal cords of vehicle- and
RTX-treated rats
We first determined the effect of DAMGO on evoked glutamatergic EPSCs from primary
afferents to spinal lamina II neurons (evoked monosynaptic EPSCs) in vehicle- and RTX-treated
rats. The concentration-response effect was tested by bath application of 0.2-2 µM DAMGO to
the slice chamber in a cumulative fashion. Each DAMGO concentration was applied for 2 min.
The baseline amplitude of evoked monosynaptic EPSCs was significantly smaller in RTX-
treated than in vehicle-treated rats (Fig. 2). DAMGO significantly inhibited the amplitude of
evoked monosynaptic EPSCs in a concentration-dependent manner in both vehicle- and RTX-
treated rats (Fig. 2). The ED50 values for the effect of DAMGO on monosynaptic EPSCs were
0.38 ± 0.06 (n = 12 cells) and 0.34 ± 0.05 µM (n = 12 cells, P > 0.05, t-test) in vehicle- and
RTX-treated rats, respectively. The maximal inhibitory effect of DAMGO on monosynaptic
EPSCs was not significantly different between the vehicle-treated (62.2 ± 5.3%) and RTX-
treated (58.7 ± 4.7%) groups.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
14
In separate groups of lamina II neurons, DAMGO also concentration dependently
inhibited the amplitude of evoked polysynaptic EPSCs (to measure glutamate release from
primary afferents and interneurons) in vehicle-treated (83.9 ± 4.1%, n = 12 cells) and in RTX-
treated (93.0 ± 2.7%, n = 9 cells, P > 0.05) rats (Fig. 3). The ED50 value for the effect of
DAMGO on polysynaptic EPSCs was not significantly different between vehicle-treated and
RTX-treated rats (0.32 ± 0.05 vs. 0.29 ± 0.04 µM, P > 0.05) . The evoked monosynaptic and
polysynaptic EPSCs were completely blocked by the non-NMDA receptor antagonist CNQX (10
µM, data not shown). Also, the inhibitory effect of 1 µM DAMGO on evoked EPSCs in vehicle-
treated (n = 6 cells) and RTX-treated (n = 8 cells) rats was abolished by 1 µM naloxone, a
specific opioid receptor antagonist.
Because DAMGO’s inhibitory effect on synaptic glutamate release persisted after
washout in RTX-treated rats (Figs. 2 and 3), we next determined the duration of the effect of
DAMGO on evoked monosynaptic EPSCs in vehicle- and RTX-treated rats. In the vehicle-
treated group, bath perfusion of 1 µM DAMGO for 3 min decreased the amplitude of the evoked
monosynaptic EPSCs by 49.4 ± 5.7% (n = 13 cells). The amplitude of EPSCs gradually
returned to the baseline level within 7 min of DAMGO washout in vehicle-treated rats (Fig. 4, A
and B). In 6 of 13 lamina II neurons, there was an immediate rebound of evoked EPSCs after
washout of DAMGO. In RTX-treated rats, bath application of 1 µM DAMGO for 3 min
produced a similar inhibitory effect (52.2 ± 3.0%; n = 12 cells; P > 0.05) on the amplitude of
evoked monosynaptic EPSCs. Strikingly, in these rats, DAMGO’s inhibitory effect on the
amplitude of EPSCs persisted, with current values remaining below the baseline for at least 15
min after DAMGO washout (Fig. 4, A and B). In another 8 lamina II neurons (4 monosynaptic
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
15
and 4 polysynaptic EPSCs) from RTX-treated rats, we found that when the spinal slices were
pretreated with 1 µM naloxone, 1 µM DAMGO failed to change significantly the amplitude of
evoked EPSCs.
Lack of reversing effect of naloxone on DAMGO-produced persistent inhibition on evoked
glutamate release in the spinal cords of RTX-treated rats
To determine whether the increased duration of the presynaptic effect of the µ-opioid
receptor agonist in RTX-treated rats is the result of increased binding affinity of the µ-opioid
receptors, we examined the effect of naloxone on the DAMGO-induced inhibition of evoked
monosynaptic EPSCs. In 8 additional lamina II neurons from RTX-treated rats, we initially
applied 1 µM DAMGO for 3 min and then bath applied 1 µM naloxone at 6 min after DAMGO
washout. Subsequent application of naloxone did not significantly reverse the long-lasting
effect of DAMGO on the amplitude of evoked EPSCs (Fig. 4B).
Effect of DAMGO on quantal glutamate release in the spinal cords of vehicle- and RTX-
treated rats
We further examined the presynaptic effect of DAMGO on quantal (action potential-
independent) glutamate release in the spinal cord of vehicle- and RTX-treated rats. The baseline
amplitude and frequency of mEPSCs were not significantly different between RTX-treated and
vehicle-treated rats. Each DAMGO concentration was applied for 2 min. Bath application of
0.2-2 µM DAMGO (each concentration was applied for 2 min) concentration-dependently
inhibited the frequency, but not the amplitude, of mEPSCs in both vehicle and RTX-treated
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
16
groups (Fig. 5). The ED50 of the effect of DAMGO on the frequency of mEPSCs was 0.28 ±
0.04 µM (n = 8) and 0.33 ± 0.03 µM (n = 10, P > 0.05) in the vehicle-treated and RTX-treated
groups, respectively. The mEPSCs were completely blocked by 10 µM CNQX.
In separate groups of lamina II neurons, we also determined the duration of the inhibitory
effect of DAMGO on mEPSCs in vehicle- and RTX-treated rats. In the vehicle group, bath
perfusion of DAMGO (1 µM) for 3 min reduced the frequency of mEPSCs by 48.5 ± 2.7% (n =
12). The frequency of mEPSCs gradually returned to the basal level approximately 8 min after
DAMGO washout (Fig. 6). Bath perfusion of DAMGO (1 µM) for 3 min produced a similar
inhibitory effect (43.9 ± 4.2%; n = 9, P > 0.05) on the frequency of mEPSCs in RTX-treated
rats. However, DAMGO produced a sustained inhibition of the frequency of mEPSCs, and this
effect did not recover for at least 15 min after DAMGO washout in RTX-treated rats (Fig. 6).
Postsynaptic effect of DAMGO in the spinal cords of vehicle- and RTX-treated rats
We then conducted experiments to determine whether the postsynaptic effect of the µ-
opioid receptor agonist in the spinal cord of RTX-treated rats differed from that in control rats.
Because the µ-opioid receptor agonist can produce GIRK currents in many lamina II neurons
(Marker et al., 2006), we used the GIRK current as a measure for the postsynaptic effect of the
µ-opioid receptor agonist. Bath application of 0.2-2 µM DAMGO (each concentration was
applied for 1 min followed by washout to baseline) evoked an outward current in a
concentration-dependent manner in both vehicle- and RTX-treated groups (Fig. 7). In the
vehicle group, 40.6% (13 of 32 cells) of lamina II neurons exhibited an outward current after
DAMGO application. In RTX-treated rats, DAMGO application produced an outward current
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
17
in 54.8% (23 of 42 cells) of lamina II neurons tested (P > 0.05, Fisher’s exact test). The
amplitude of the GIRK current produced by DAMGO was not significantly different between the
vehicle-treated and RTX-treated groups. DAMGO at 2 µM produced a maximal current
response in both vehicle-treated (29.8 ± 2.3 pA; n = 11 cells) and in RTX-treated (34.7 ± 2.7
pA; n = 17 cells) rats (P > 0.05). The DAMGO-elicited GIRK currents were completely blocked
in the presence of the opioid receptor antagonist naloxone (1 µM) or when 1 mM GDP-β-S was
included in the pipette internal solution for all the lamina II neurons examined (data not shown).
To further examine the duration of the effect of DAMGO on GIRK currents, we
examined the effect of bath application of 1 µM DAMGO for 3 min in separate groups of lamina
II neurons in vehicle-treated and RTX-treated rats. The duration of DAMGO’s effect on GIRK
currents was measured from the beginning of the GIRK current to the time at which the current
decay reached 20% of the maximal current. Upon washout of DAMGO, its effect on GIRK
currents rapidly disappeared within 6 min in both groups. The duration of DAMGO-produced
GIRK currents was not significantly different between the vehicle-treated (4.66 ± 0.46 min, n =
12 cells) and RTX-treated (5.49 ± 0.44 min, n = 16 cells) rats (Fig. 8).
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
18
Discussion
The most salient finding of the present study is that activation of µ-opioid receptors
produced long-lasting inhibition of synaptic glutamate release from primary afferent terminals
when TRPV1-expressing afferent terminals were removed. We found that the concentration-
response and maximal inhibition of evoked monosynaptic and polysynaptic EPSCs and mEPSCs
by the µ-opioid receptor agonist DAMGO were not significantly different between vehicle- and
RTX-treated rats. However, briefly applying DAMGO to the spinal cord slices caused a striking
prolongation of its inhibitory effect on monosynaptic evoked EPSCs and mEPSCs in RTX-
treated rats. Also, naloxone did not readily reverse the prolonged presynaptic effect of DAMGO
in RTX-treated rats, which is consistent to our previous finding that the binding affinity of the
µ-opioid receptors is not altered by RTX treatment (Chen and Pan, 2006b). We observed that
the concentration-response of GIRK currents evoked by DAMGO and the duration of the effect
were similar in vehicle- and RTX-treated rats. Our study demonstrates that stimulation of the µ-
opioid receptors produces a long-lasting inhibition of glutamate release from non-TRPV1-
expressing primary afferent terminals. Our findings also suggest that the desensitization process
of µ-opioid receptors located on TRPV1- and non-TRPV1-expressing nociceptive afferent
terminals may be distinctly different.
Systemic administration of RTX induces a substantial reduction in presynaptic µ-opioid
receptors in the spinal cord because TRPV1-expressing afferent neurons are lost (Chen and Pan,
2006b). However, the analgesic effect of the µ-opioid receptor agonists, morphine and
DAMGO, is potentiated in RTX-treated rats (Chen and Pan, 2006b). RTX treatment also
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
19
attenuates the development of morphine analgesic tolerance (Chen et al., 2007). The cellular
and molecular mechanisms underlying the altered opioid action in RTX-treated rats are little
known. The µ-opioid receptor agonists inhibit glutamatergic synaptic transmission in the spinal
dorsal horn (Kohno et al., 1999). The presynaptic effect of µ-opioid receptor agonists is
mediated by their inhibitory effect on voltage-gated Ca2+ channels (Rusin and Moises, 1995; Wu
et al., 2004) and the direct inhibitory effect on the transmitter release machinery, by binding to
proteins of the SNARE complex (Blackmer et al., 2005; Gerachshenko et al., 2005).
Postsynaptically, the µ-opioid receptor agonists inhibit the excitability of spinal dorsal horn
neurons by opening GIRK channels (Schneider et al., 1998; Marker et al., 2006). These
combined presynaptic and postsynaptic effects of µ-opioid receptor agonists contribute to their
analgesic action in the spinal cord. We therefore examined the presynaptic and postsynaptic
effects of the µ-opioid receptor agonist in the spinal cord to determine the cellular mechanisms
underlying potentiated opioid analgesia after removing TRPV1-expressing afferent neurons. We
observed that the baseline amplitude of EPSCs was significantly smaller in RTX-treated than in
vehicle-treated rats. Our immunocytochemical studies documented the reduction in IB4-positive
afferent terminals and the depletion of TRPV1 immunoreactivity in the DRG and superficial
dorsal horn of RTX-treated rats. Also, the histological study has shown that RTX treatment
causes a large reduction in unmyelinated fibers in the sciatic nerve (Pan et al., 2003). Thus, the
reduced glutamatergic input evoked from primary afferents is likely due to the removal of
TRPV1-expressing afferent terminals in the spinal dorsal horn by RTX treatment. Despite the
fact that the number of µ-opioid receptors in the spinal cord is significantly reduced in RTX-
treated rats, as shown by our previous study (Chen and Pan, 2006b), we found that DAMGO
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
20
inhibited evoked monosynaptic and polysynaptic glutamatergic EPSCs and mEPSCs in a
concentration-dependent manner, and that these effects were not significantly different between
vehicle- and RTX-treated rats. These data suggest that stimulation of the remaining µ-opioid
receptors on non-TRPV1-expressing primary afferents can potently inhibit neurotransmitter
release to spinal dorsal horn neurons. Because DAMGO similarly inhibited EPSCs evoked from
the primary afferents in vehicle-treated and RTX-treated rats, it is unlikely that the increased
opioid analgesia in RTX-treated rats was due to the difference in the µ-opioid receptor density
between TRPV1- and non-TRPV1-expressing primary afferents.
To our knowledge, this is the first study demonstrating that activation of µ-opioid
receptors can cause sustained inhibition of glutamate release from non-TRPV1-expressing
primary afferent terminals in the spinal cord. We found that in vehicle-treated rats, brief
exposure of the spinal cord slices to DAMGO inhibited evoked monosynaptic EPSCs, and this
effect disappeared rapidly after drug washout. In contrast, the DAMGO-induced inhibition of
monosynaptic EPSCs in RTX-treated rats became long-lasting, persisting for at least 15 min
after DAMGO washout. When the TRPV1-expressing primary afferents were intact, we found
that there was an immediate rebound of evoked EPSCs in some lamina II neurons after washout
of DAMGO. Thus, the sustained inhibitory effect of DAMGO on synaptic glutamate release
from non-TRPV1-expressing afferents might be masked by the presence of TRPV1-expressing
afferent terminals. The precise cellular mechanisms underlying this prolonged presynaptic
action in RTX-treated rats remain to be determined. Because subsequent treatment with
naloxone failed to reverse the long-lasting inhibitory effect of DAMGO on evoked EPSCs in
RTX-treated rats, it is less likely that the prolonged presynaptic effect of DAMGO is due to
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
21
increased binding affinity of surface µ-opioid receptors in the spinal cord by RTX treatment.
We also found that DAMGO caused a persistent inhibition of the frequency of mEPSCs, a
measure of quantal vesicle release independent of voltage-activated Ca2+ channels, in spinal
dorsal horn neurons of RTX-treated rats. The effect of the µ-opioid receptor agonist on mEPSCs
is possibly due to direct inhibition of the vesicle release machinery, such as SNAP25 (Capogna
et al., 1993; Gerachshenko et al., 2005). Our findings suggest that the prolonged inhibitory
effect of the µ-opioid receptor agonist at non-TRPV1-expressing afferent terminals is not the
results of increased coupling between the µ-opioid receptor and voltage-activated Ca2+ channels.
It is known that the µ-opioid receptors are desensitized/inactivated by G protein-coupled
receptor kinases (Celver et al., 2004), β-arrestins (Bohn et al., 1999; Bohn et al., 2000), and
protein kinase C (PKC) (Narita et al., 2001). In β-arrestin2-knockout mice, presynaptic
inhibition of GABA release by the µ-opioid receptor agonist is enhanced, whereas the
postsynaptic GIRK currents elicited by the µ-opioid receptor agonist are not affected in the locus
coeruleus and periaqueductal gray (Bradaia et al., 2005). Thus, if β-arrestins are inadequately
expressed in TRPV1-negative primary afferents, it could explain why the presynaptic inhibitory
effect of the µ-opioid receptor agonist in the spinal cord is sustained in RTX-treated rats.
Furthermore, the analgesic effect produced by µ-opioid receptor agonists is potentiated in PKC-
knockout mice (Narita et al., 2001). Because PKC is mainly expressed in IB4-positive (mostly
TRPV1-expressing) DRG neurons (Molliver et al., 1995), the differential expression of PKC in
TRPV1- and non-TRPV1-sensory neurons may profoundly influence the rate of µ-opioid
receptor desensitization/inactivation. We have shown that morphine analgesic tolerance is
attenuated in RTX-treated rats (Chen et al., 2007). If RTX treatment predominantly removes
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
22
TRPV1-containing afferent terminals in which the µ-opioid receptors are co-expressed with a
high level of PKCγ (Chen et al., 2007), it could prolong the presynaptic effect of the µ-opioid
receptor agonist. Further studies are warranted to determine the differential expression of the
signaling molecules involved in µ-opioid receptor desensitization in TRPV1- and non-TRPV1-
expressing sensory neurons.
Activation of GIRK channels by the µ-opioid receptor agonist can reduce neuronal
excitability and inhibit nociceptive transmission in the spinal cord (Schneider et al., 1998;
Marker et al., 2006). This postsynaptic effect contributes to the analgesic action of the µ-opioid
receptor agonists (Ikeda et al., 2000; Marker et al., 2005). Because removal of TRPV1-
expressing primary afferents may cause an upregulation of postsynaptic µ-opioid receptors, we
further examined the postsynaptic effect of the µ-opioid receptor agonist in the spinal cord of
RTX-treated rats. We observed that the concentration-response and the duration of effects of
DAMGO on GIRK currents were not significantly different between vehicle-treated and RTX-
treated rats. Thus, it is less likely that the potentiated analgesic effect of the µ-opioid receptor
agonist in RTX-treated rats is due to changes in the postsynaptic µ-opioid receptors.
In summary, the present study demonstrates that deleting TRPV1-expressing sensory
neurons preferentially increases the duration of the presynaptic inhibitory effect of the µ-opioid
receptor agonist in the spinal cord. This persistent presynaptic inhibition by the µ-opioid
receptor agonist could explain the prolonged duration of opioid analgesia found when TRPV1-
expressing primary afferents are absent (Chen and Pan, 2006b). Our findings provide a cellular
basis for the possible differential signaling of µ-opioid receptors in different populations of
nociceptive primary afferent terminals. This information is also important for our understanding
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
23
of how µ-opioid receptor agonists produce a more prolonged analgesic effect on mechanical
nociception than thermal (TRPV1-mediated) nociception, which may ultimately improve the
clinical use of opioid therapy for different pain states.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
24
References
Abbadie C, Lombard MC, Besson JM, Trafton JA and Basbaum AI (2002) Mu and delta opioid
receptor-like immunoreactivity in the cervical spinal cord of the rat after dorsal
rhizotomy or neonatal capsaicin: an analysis of pre- and postsynaptic receptor
distributions. Brain Res. 930:150-162.
Blackmer T, Larsen EC, Bartleson C, Kowalchyk JA, Yoon EJ, Preininger AM, Alford S, Hamm
HE and Martin TF (2005) G protein betagamma directly regulates SNARE protein fusion
machinery for secretory granule exocytosis. Nat Neurosci 8:421-425.
Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ and Caron MG (2000) Mu-opioid receptor
desensitization by beta-arrestin-2 determines morphine tolerance but not dependence.
Nature 408:720-723.
Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG and Lin FT (1999) Enhanced
morphine analgesia in mice lacking beta-arrestin 2. Science 286:2495-2498.
Bradaia A, Berton F, Ferrari S and Luscher C (2005) beta-Arrestin2, interacting with
phosphodiesterase 4, regulates synaptic release probability and presynaptic inhibition by
opioids. Proc Natl Acad Sci U S A 102:3034-3039.
Capogna M, Gahwiler BH and Thompson SM (1993) Mechanism of mu-opioid receptor-
mediated presynaptic inhibition in the rat hippocampus in vitro. J Physiol 470:539-558.
Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR, Koltzenburg
M, Basbaum AI and Julius D (2000) Impaired nociception and pain sensation in mice
lacking the capsaicin receptor. Science 288:306-313.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
25
Celver J, Xu M, Jin W, Lowe J and Chavkin C (2004) Distinct domains of the mu-opioid
receptor control uncoupling and internalization. Mol Pharmacol 65:528-537.
Chen SR and Pan HL (2006a) Blocking mu opioid receptors in the spinal cord prevents the
analgesic action by subsequent systemic opioids. Brain Res 1081:119-125.
Chen SR and Pan HL (2006b) Loss of TRPV1-expressing sensory neurons reduces spinal mu
opioid receptors but paradoxically potentiates opioid analgesia. J Neurophysiol 95:3086-
3096.
Chen SR, Prunean A, Pan HM, Welker KL and Pan HL (2007) Resistance to morphine analgesic
tolerance in rats with deleted transient receptor potential vanilloid type 1-expressing
sensory neurons. Neuroscience 145:676-685.
Cui M, Honore P, Zhong C, Gauvin D, Mikusa J, Hernandez G, Chandran P, Gomtsyan A,
Brown B, Bayburt EK, Marsh K, Bianchi B, McDonald H, Niforatos W, Neelands TR,
Moreland RB, Decker MW, Lee CH, Sullivan JP and Faltynek CR (2006) TRPV1
receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists.
J Neurosci 26:9385-9393.
Fields HL, Emson PC, Leigh BK, Gilbert RF and Iversen LL (1980) Multiple opiate receptor
sites on primary afferent fibres. Nature 284:351-353.
Gerachshenko T, Blackmer T, Yoon EJ, Bartleson C, Hamm HE and Alford S (2005)
Gbetagamma acts at the C terminus of SNAP-25 to mediate presynaptic inhibition. Nat
Neurosci 8:597-605.
Ikeda K, Kobayashi T, Kumanishi T, Niki H and Yano R (2000) Involvement of G-protein-
activated inwardly rectifying K (GIRK) channels in opioid-induced analgesia. Neurosci
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
26
Res 38:113-116.
Kohno T, Kumamoto E, Higashi H, Shimoji K and Yoshimura M (1999) Actions of opioids on
excitatory and inhibitory transmission in substantia gelatinosa of adult rat spinal cord. J
Physiol 518:803-813.
Light AR and Willcockson HH (1999) Spinal laminae I-II neurons in rat recorded in vivo in
whole cell, tight seal configuration: properties and opioid responses. J Neurophysiol
82:3316-3326.
Magnuson DS and Dickenson AH (1991) Lamina-specific effects of morphine and naloxone in
dorsal horn of rat spinal cord in vitro. J Neurophysiol 66:1941-1950.
Marker CL, Lujan R, Colon J and Wickman K (2006) Distinct populations of spinal cord lamina
II interneurons expressing G-protein-gated potassium channels. J Neurosci 26:12251-
12259.
Marker CL, Lujan R, Loh HH and Wickman K (2005) Spinal G-protein-gated potassium
channels contribute in a dose-dependent manner to the analgesic effect of mu- and delta-
but not kappa-opioids. J Neurosci 25:3551-3559.
Molliver DC, Radeke MJ, Feinstein SC and Snider WD (1995) Presence or absence of TrkA
protein distinguishes subsets of small sensory neurons with unique cytochemical
characteristics and dorsal horn projections. J Comp Neurol 361:404-416.
Narita M, Mizoguchi H, Suzuki T, Dun NJ, Imai S, Yajima Y, Nagase H and Tseng LF (2001)
Enhanced mu-opioid responses in the spinal cord of mice lacking protein kinase
Cgamma isoform. J Biol Chem 276:15409-15414.
Pan HL, Khan GM, Alloway KD and Chen SR (2003) Resiniferatoxin induces paradoxical
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
27
changes in thermal and mechanical sensitivities in rats: mechanism of action. J Neurosci
23:2911-2919.
Rusin KI and Moises HC (1995) mu-Opioid receptor activation reduces multiple components of
high-threshold calcium current in rat sensory neurons. J Neurosci 15:4315-4327.
Schneider SP, Eckert WA, 3rd and Light AR (1998) Opioid-activated postsynaptic, inward
rectifying potassium currents in whole cell recordings in substantia gelatinosa neurons. J
Neurophysiol 80:2954-2962.
Walker KM, Urban L, Medhurst SJ, Patel S, Panesar M, Fox AJ and McIntyre P (2003) The
VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of
inflammatory and neuropathic pain. J Pharmacol Exp Ther 304:56-62.
Woodbury CJ, Ritter AM and Koerber HR (2000) On the problem of lamination in the
superficial dorsal horn of mammals: a reappraisal of the substantia gelatinosa in
postnatal life. J Comp Neurol 417:88-102.
Wu ZZ, Chen SR and Pan HL (2004) Differential sensitivity of N- and P/Q-type Ca2+ channel
currents to a mu opioid in isolectin B4-positive and -negative dorsal root ganglion
neurons. J Pharmacol Exp Ther 311:939-947.
Yaksh TL and Noueihed R (1985) The physiology and pharmacology of spinal opiates. Annu
Rev Pharmacol Toxicol 25:433-462.
Zhang HM, Chen SR and Pan HL (2007) Regulation of glutamate release from primary afferents
and interneurons in the spinal cord by muscarinic receptor subtypes. J Neurophysiol
97:102-109.
Zhou HY, Zhang HM, Chen SR and Pan HL (2007) Increased nociceptive input rapidly
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
28
modulates spinal GABAergic transmission through endogenously released glutamate. J
Neurophysiol 97:871-882.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
29
Footnotes
This study was supported by grants GM64830 and NS45602 from the National Institutes
of Health.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
30
Legends for Figures
Fig. 1. Confocal images showing the effect of RTX on TRPV1- and IB4-positive dorsal root
ganglion (DRG) neurons and afferent terminals in the spinal cord. A: representative confocal
images showing TRPV1 (green)-immunoreactive and IB4-positive (red) DRG neurons from one
vehicle-treated and one RTX-treated rat. B: confocal images showing TRPV1 (green)-
immunoreactive and IB4-positive (red) afferent terminals in the spinal dorsal horn of one
vehicle- and one RTX-treated rat. Co-localization of TRPV1 immunoreactivity and IB4 labeling
is indicated in yellow when two images are digitally merged. All images are single confocal
optical sections.
Fig. 2. Effect of DAMGO on evoked monosynaptic EPSCs of lamina II neurons in vehicle-
treated and RTX-treated rats. A, original current traces showing the effect of different
concentrations (0.2-2 µM) of DAMGO on monosynaptic EPSCs of lamina II neurons in one
vehicle- and one RTX-treated rat. B, concentration-response curve of the effect of 0.2-2 µM
DAMGO on the peak amplitude (left) and percentage of inhibition (right) of monosynaptic
EPSCs of lamina II neurons in vehicle-treated (n = 12 cells) and RTX-treated (n = 12 cells) rats.
*, P < 0.05 compared with the control value. #, P < 0.05 compared with the corresponding
value in the vehicle group.
Fig. 3. Effect of DAMGO on evoked polysynaptic EPSCs of lamina II neurons in vehicle-
treated and RTX-treated rats. A, representative traces showing the effect of 0.2-2 µM DAMGO
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
31
on the peak amplitude (left) and percentage of inhibition (right) of polysynaptic EPSCs in one
vehicle- and one RTX-treated rat. B, concentration-response curve of the effect of 0.2-2 µM
DAMGO on the amplitude of polysynaptic EPSCs of lamina II neurons in vehicle-treated (n =
12 cells) and RTX-treated (n = 9 cells) rats. *, P < 0.05 compared with the control value. #, P <
0.05 compared with the corresponding value in the vehicle group.
Fig. 4. Durations of the inhibitory effect of DAMGO (1 µM for 3 min) on evoked monosynaptic
EPSCs of lamina II neurons in vehicle-treated and RTX-treated rats. A, original traces showing
the monosynaptic EPSCs during the control period, during application of 1 µM DAMGO, and at
different time points after DAMGO washout in one vehicle- and one RTX-treated rat. B, time
course of the persistent inhibitory effect of 1 µM DAMGO after washout on the peak amplitude
of monosynaptic EPSCs of lamina II neurons in vehicle-treated (n = 13 cells) and RTX-treated
(n = 12 cells) rats. Note that subsequent application of 1 µM naloxone for 3 min did not reverse
the persistent inhibitory effect of 1 µM DAMGO in another 8 lamina II neurons from RTX-
treated rats. *, P < 0.05 compared with the respective control value. #, P < 0.05 compared with
corresponding value in the vehicle group.
Fig. 5. Effect of DAMGO on mEPSCs in lamina II neurons in vehicle-treated and RTX-treated
rats. A, original traces showing the effect of different concentrations of DAMGO on mEPSCs in
a lamina II neuron from a vehicle-treated and an RTX-treated rat. B, concentration-response
curves showing the inhibitory effect of DAMGO on the frequency of mEPSCs in lamina II
neurons from the vehicle treated and RTX-treated rats. *, P < 0.05 compared with the
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
32
respective control. Cont, control.
Fig. 6. Duration of the inhibitory effect of DAMGO on mEPSCs in lamina II neurons from
vehicle-treated and RTX-treated rats. A, original traces showing the time course and duration of
the DAMGO (1 µM for 3 min)-induced changes in the mEPSC frequency in a lamina II neuron
from a vehicle-treated and an RTX-treated rat. B, summary data showing the duration of the
inhibitory effect of DAMGO (1 µM for 3 min) on the frequency of mEPSCs in lamina II neurons
from the vehicle-treated and RTX-treated rats. *, P < 0.05 compared with the respective control.
Cont, control.
Fig. 7. Effect of DAMGO on postsynaptic GIRK currents of lamina II neurons in vehicle-treated
and RTX-treated rats. A, original current traces showing the effect of different concentrations
(0.2-2 µM) of DAMGO on GIRK currents of lamina II neurons in one vehicle-treated and one
RTX-treated rat. B, concentration-response curve of the inhibitory effect of 0.2-2 µM DAMGO
on the peak amplitude of GIRK currents of lamina II neurons in vehicle-treated (n = 11 cells)
and RTX-treated (n = 17 cells) rats. *, P < 0.05 compared with the respective control value.
Fig. 8. Duration of the effect of DAMGO (1 µM for 3 min) on GIRK currents of lamina II
neurons in vehicle-treated and RTX-treated rats. A, original recordings showing the GIRK
current of lamina II neurons produced by application of 1 µM DAMGO in one vehicle-treated
and one RTX-treated rat. B, comparison of the duration of the effect of 1 µM DAMGO on
GIRK currents of lamina II neurons in vehicle-treated (n = 12 cells) and RTX-treated (n = 16
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
JPET #141226
33
cells) rats.
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from
This article has not been copyedited and formatted. The final version may differ from this version.JPET Fast Forward. Published on July 31, 2008 as DOI: 10.1124/jpet.108.141226
at ASPE
T Journals on February 4, 2020
jpet.aspetjournals.orgD
ownloaded from